HK1090275A1 - Prion-specific peptide reagents - Google Patents

Prion-specific peptide reagents

Info

Publication number
HK1090275A1
HK1090275A1 HK06112300.4A HK06112300A HK1090275A1 HK 1090275 A1 HK1090275 A1 HK 1090275A1 HK 06112300 A HK06112300 A HK 06112300A HK 1090275 A1 HK1090275 A1 HK 1090275A1
Authority
HK
Hong Kong
Prior art keywords
prion
specific peptide
peptide reagents
reagents
specific
Prior art date
Application number
HK06112300.4A
Other languages
English (en)
Inventor
Melissa D Michelitsch
Celine Hu
Roland N Zuckermann
Michael D Connolly
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of HK1090275A1 publication Critical patent/HK1090275A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
HK06112300.4A 2003-08-13 2006-11-08 Prion-specific peptide reagents HK1090275A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49496203P 2003-08-13 2003-08-13
US57036804P 2004-05-12 2004-05-12
US58650904P 2004-07-09 2004-07-09
PCT/US2004/026363 WO2005016127A2 (fr) 2003-08-13 2004-08-13 Reactifs peptidiques specifiques du prion

Publications (1)

Publication Number Publication Date
HK1090275A1 true HK1090275A1 (en) 2006-12-22

Family

ID=34198970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06112300.4A HK1090275A1 (en) 2003-08-13 2006-11-08 Prion-specific peptide reagents

Country Status (14)

Country Link
US (1) US7439041B2 (fr)
EP (1) EP1653844B1 (fr)
JP (3) JP4709149B2 (fr)
KR (1) KR101166012B1 (fr)
AU (2) AU2004264953B2 (fr)
BR (1) BRPI0413495A (fr)
CA (1) CA2535261C (fr)
DK (1) DK1653844T3 (fr)
ES (1) ES2398394T3 (fr)
HK (1) HK1090275A1 (fr)
IL (1) IL173480A0 (fr)
MX (1) MXPA06001588A (fr)
NZ (2) NZ580256A (fr)
WO (1) WO2005016127A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395833B1 (fr) * 2001-05-31 2013-02-27 Adlyfe, Inc. Procede de detection de proteines mal pliees
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
JP4709149B2 (ja) * 2003-08-13 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
US20060057671A1 (en) * 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
WO2006076683A2 (fr) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolement et detection de prions pathogenes
JP5162250B2 (ja) * 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
US20090099343A1 (en) 2005-01-13 2009-04-16 David Peretz Isolation of pathogenic prions
MX2007009819A (es) * 2005-02-15 2007-11-07 Adlyfe Inc Metodo para detectar proteinas y priones desplegados.
MX2007014565A (es) * 2005-06-01 2008-02-11 Micromet Ag Anticuerpos anti-il2.
WO2007030804A1 (fr) 2005-09-09 2007-03-15 Novartis Ag Reactifs peptoides specifiques des prions
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
WO2008013859A2 (fr) * 2006-07-28 2008-01-31 Adlyfe, Inc. Sondes peptidiques pour des diagnostics et des produits thérapeutiques
JP2010523977A (ja) * 2007-04-04 2010-07-15 ノバルティス アーゲー プリオンアッセイ
CA2684798A1 (fr) * 2007-04-04 2008-10-16 Novartis Ag Dosage immuno-enzymatique (elisa) du prion
WO2009041902A1 (fr) * 2007-09-25 2009-04-02 Loefgren Kajsa Peptides pénétrant une cellule dérivée d'une protéine prion et leurs utilisations
US8709472B1 (en) * 2007-11-13 2014-04-29 Abbott Cardiovascular Systems Inc. Bioactive agent-loaded heart-targeting nanoparticles
CA2721982A1 (fr) * 2008-04-30 2009-11-05 Novartis Ag Essai de conformeres pathogenes
EP2128618A1 (fr) * 2008-05-30 2009-12-02 Prion Diagnostica S.r.l. Procédé pour le suivi de la présence d'agents pathogènes dans des fluides biologiques par des matériaux nanostructurés
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
WO2012051498A2 (fr) * 2010-10-15 2012-04-19 The Board Of Regents Of The University Of Texas System Anticorps qui lient des oligomères amyloïdes
JP7011830B2 (ja) 2015-10-14 2022-01-27 エックス－サーマ インコーポレイテッド 氷晶形成を低減するための組成物および方法
AU2017263706B2 (en) * 2016-05-10 2020-04-09 Lg Electronics Inc. Mobile robot and control method therefor
WO2018005330A1 (fr) * 2016-06-27 2018-01-04 Florida State University Research Foundation, Inc. Fragments modifiés de la région d'octarépétition de la protéine de prion en tant qu'agents de liaison d'hémine
WO2018053472A1 (fr) * 2016-09-19 2018-03-22 University Of Houston System Composition et méthodes de ciblage de cellules souches cancéreuses
JP2021004175A (ja) * 2017-09-04 2021-01-14 国立大学法人東北大学 コンフォメーション病治療用材料、及びその製造方法、並びにコンフォメーション病医薬のスクリーニング方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675053B2 (en) 1991-12-03 1997-01-23 Proteus Molecular Design Limited Fragments of prion proteins
AU4376093A (en) 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
EP0852011B1 (fr) 1995-09-14 2004-03-31 The Regents of the University of California ANTICORPS SPECIFIQUE DU PrP?Sc NATIF
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
AU738606B2 (en) 1997-02-06 2001-09-20 Enfer Technology Limited Immunological assay for spongiform encephalopathies
EP0861900A1 (fr) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Détection immunologique de prions
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
CA2369172A1 (fr) * 1998-04-14 1999-10-21 Sugen, Inc. Proteines kinases apparentees a la famille de ste20
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
AU3474100A (en) 1999-01-25 2000-08-07 Minerva Biotechnologies Corporation Rapid and sensitive detection of aberrant protein aggregation in neurodegenerative diseases
ATE348632T1 (de) 1999-06-23 2007-01-15 Caprion Pharmaceuticals Inc Prion protein peptide und deren verwendung
CA2379237A1 (fr) 1999-07-27 2001-02-01 Imperial College Innovations Limited Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
JP2003514773A (ja) * 1999-09-28 2003-04-22 ウニヴェルジテート チューリッヒ 血清及び血漿中のプリオン結合活性を有する因子並びに伝染性海綿状脳障害を検出するための薬剤
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
CA2405568A1 (fr) 2000-04-05 2001-10-18 North Carolina State University Ligands de fixation au prion et procedes d'utilisation correspondants
US6642171B2 (en) * 2000-04-28 2003-11-04 Synuthane International, Inc. Double metal cyanide catalysts containing polyglycol ether complexing agents
IL148202A0 (en) 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
SI1712920T1 (sl) 2000-07-07 2009-10-31 Merck Serono Sa Zgodnja diagnoza konformacijskih bolezni
GB0103508D0 (en) * 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
EP1395833B1 (fr) 2001-05-31 2013-02-27 Adlyfe, Inc. Procede de detection de proteines mal pliees
US7479482B2 (en) 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
JP2005514385A (ja) 2001-12-10 2005-05-19 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ プリオン阻害ペプチド及びその誘導体
WO2003073106A2 (fr) 2002-02-28 2003-09-04 Microsens Biophage Limited Liaison de formes pathologiques de proteines prion
EP1572937B1 (fr) 2002-04-09 2012-02-08 The Scripps Research Institute Polypeptides hybrides a greffe de motif structural et utilisations de ceux-ci
US20040208919A1 (en) 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (fr) 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection de maladie a prion
US20060057636A1 (en) 2002-08-21 2006-03-16 Peter Heegaard Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
WO2004037854A1 (fr) 2002-10-23 2004-05-06 Centre For Research And Technology Hellas/Institute Of Agrobiotechnology In.A Sequences peptidiques liant la proteine prion
WO2004046728A1 (fr) 2002-11-18 2004-06-03 Prionics Ag Methode de detection de prpsc
US7863411B2 (en) 2002-12-03 2011-01-04 Pathogen Removal and Diagnostics Technologies Inc. Prion protein ligands and methods of use
EP1457500A1 (fr) 2003-03-14 2004-09-15 University of Zurich Proteinés solubles de prion hybrids et leurs utilisations en diagnostique, prévention et traítement de l'encephalopathie spongiforme transmissible
CN1842707B (zh) 2003-04-04 2012-06-27 病毒去除和诊断科技公司 朊病毒蛋白结合材料及其使用方法
EP1616036A4 (fr) 2003-04-14 2007-03-21 Pathogen Removal And Diagnosti Procede d'identification de ligands specifiques pour des isoformes structurales de proteines
JP4709149B2 (ja) * 2003-08-13 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins

Also Published As

Publication number Publication date
KR101166012B1 (ko) 2012-07-23
JP2010158247A (ja) 2010-07-22
ES2398394T3 (es) 2013-03-15
US7439041B2 (en) 2008-10-21
JP2007502120A (ja) 2007-02-08
WO2005016127A2 (fr) 2005-02-24
AU2009225337A1 (en) 2009-11-05
BRPI0413495A (pt) 2006-10-17
NZ545385A (en) 2010-12-24
US20050118645A1 (en) 2005-06-02
AU2004264953A1 (en) 2005-02-24
EP1653844A2 (fr) 2006-05-10
CA2535261A1 (fr) 2005-02-24
DK1653844T3 (da) 2013-03-11
CA2535261C (fr) 2015-11-24
MXPA06001588A (es) 2006-08-25
AU2009225337B2 (en) 2012-12-06
KR20060066088A (ko) 2006-06-15
JP2013033060A (ja) 2013-02-14
EP1653844A4 (fr) 2009-01-14
NZ580256A (en) 2011-07-29
AU2004264953B2 (en) 2009-07-23
IL173480A0 (en) 2006-06-11
WO2005016127A3 (fr) 2006-12-21
JP4709149B2 (ja) 2011-06-22
EP1653844B1 (fr) 2012-12-12

Similar Documents

Publication Publication Date Title
HK1090275A1 (en) Prion-specific peptide reagents
GB0324265D0 (en) Peptide
GB0311108D0 (en) Proteins
GB0322998D0 (en) Protein
GB0324466D0 (en) Peptides
GB0326303D0 (en) Peptides
GB0306980D0 (en) Proteins
GB0300506D0 (en) Proteins
GB0304661D0 (en) Proteins
GB0304921D0 (en) Proteins
GB0305576D0 (en) Proteins
GB0330036D0 (en) Proteins
GB0304656D0 (en) Proteins
GB0300503D0 (en) Proteins
GB0318686D0 (en) Proteins
GB0319586D0 (en) Proteins
GB0326291D0 (en) Proteins
GB0326636D0 (en) Proteins
GB0329145D0 (en) Proteins
GB0329664D0 (en) Proteins
GB0316704D0 (en) Protein
GB0300717D0 (en) Protein
GB0321297D0 (en) Protein
GB0321071D0 (en) Protein
GB0319710D0 (en) Protein

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180817